|Mr. Ronald A. Andrews Jr.||CEO, Pres & Director||978.35k||N/A||1960|
|Mr. Mitchell S. Levine||Chief Financial Officer||509.23k||N/A||N/A|
|Ms. Padma Sundar||Chief Commercial Officer||365.22k||N/A||N/A|
|Ms. Li Yu||VP, Controller & Principal Accounting Officer||N/A||N/A||N/A|
|Mr. William Annett||Advisor||N/A||N/A||1954|
|Dr. Douglas T. Ross M.D., Ph.D.||Chief Science Officer||N/A||N/A||N/A|
|Dr. Michael D. West||Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.||N/A||N/A||1953|
|Ms. Sara Riordan||Director of Medical Education||N/A||N/A||N/A|
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California.
OncoCyte Corporation’s ISS Governance QualityScore as of July 1, 2021 is 4. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 1; Compensation: 7.